Loading...
Overcoming tumor-induced blockade of innate anticancer immunity is increasingly important across cancer subtypes.
Now, investigators report the results of a phase I study in which 15 patients with diffuse large B-cell lymphoma (DLBCL) and 7 patients with relapsed or refractory follicular lymphoma (FL) were treated with the 5F9 monoclonal antibody targeting CD47, a “don't eat me” signal expressed by some lymphomas that blocks macrophage ingestion. Patients received low-dose 5F9 (1 mg/kg) in week 1, followed by weekly 5F9 (10–30 mg/kg) plus rituximab. All patients were heavily pretreated, and 95% were rituximab refractory.
Among DLBCL patients, 40% responded, and 33% had complete responses. Among FL patients, 71% responded, and 43% had complete…